WO2006102418A2 - Implantable devices formed of non-fouling methacrylate or acrylate polymers - Google Patents
Implantable devices formed of non-fouling methacrylate or acrylate polymers Download PDFInfo
- Publication number
- WO2006102418A2 WO2006102418A2 PCT/US2006/010420 US2006010420W WO2006102418A2 WO 2006102418 A2 WO2006102418 A2 WO 2006102418A2 US 2006010420 W US2006010420 W US 2006010420W WO 2006102418 A2 WO2006102418 A2 WO 2006102418A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- poly
- methacrylate
- rapamycin
- acrylate
- polymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/064—Use of macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
Definitions
- This invention generally relates to coatings or implantable devices, such as stents or coatings on a stent, formed of a material that contains methacrylates or acrylates having non-fouling pendant groups.
- compositions provide to stents described therein an enhanced biocompatibility and may optionally include a bioactive agent.
- U.S. Patent No. 6,231,590 to Scimed Life Systems, Inc. describes a coating composition, which includes a bioactive agent, a collagenous material, or a collagenous coating optionally containing or coated with other bioactive agents.
- a current paradigm in biomaterials is the control of protein adsorption on the implant surface. Uncontrolled protein adsorption, leading to mixed layer of partially denatured proteins, is a hallmark of current biomaterials when implanted. Such a surface presents different cell binding sites from adsorbed plasma proteins such as fibrogen and immunogloblulin G. Platelets and inflammatory cells such as monocyte/macrophages and neutrophils adhere to these surfaces. Unfavorable events can be controlled by the use of non-fouling surfaces. These are materials, which absorb little or no protein, primarily due to their hydrophilic surface properties.
- a biomaterials- based strategy for further improving the outcome of drug-delivery stents is by the use of biobeneficial materials or surfaces in stent coatings.
- a biobeneficial material is one which enhances the biocompatibility of a device by being non-fouling, hemocompatible, actively non-thrombogenic, or anti-inflammatory, all without depending on the release of a pharmaceutically active agent.
- poly(vinylidene fluoride-co-hexafluoropropene) have good mechanical properties, and acceptable biocompatibility, but also have low permeability to drugs.
- One proposed solution to ameliorate this issue is to blend in hydrophilic polymers.
- hydrophilic materials such as polyethylene oxide or hyaluronic acid are water-soluble and can be leached out of the composition such that the coating may lose biobeneficiality.
- Such polymeric blends can also have compromised mechanical properties, particularly the ultimate elongation.
- the present invention addresses such problems by providing a polymeric material for coating implantable devices by providing polymeric materials from which the device can be made.
- the polymer can be a polymer that contains repeating units of Formula I:
- R 1 , R 2 , R 3 , R 4 and R 5 are independently H, C1-C4 alkyl such as CH 3 , ethyl, propyl, isopropyl, isobutyl, sec-butyl, or n-butyl, silyl groups, siloxy groups, and phenyl,
- Z is O or NH
- X is absence, O, S, or NR 6 where R 6 is H, C1-C4 alkyl such as CH 3 , ethyl, propyl, isopropyl, or n-butyl, and phenyl, and n can be 0 or a positive integer ranging from, e.g., 1 to 100,000.
- the polymer that contains the repeating units of Formula I can be a homopolymer or a copolymer.
- the copolymer can be, statistical, random, alternating, periodic block or graft copolymer including the repeating units of Formula I, and include other repeating units such as a biocompatible polymer, and/or a biobeneficial material.
- the polymer defined herein can be used alone or in combination with another biocompatible polymer and/or a biobeneficial material to form coatings on implantable medical devices or to form the implantable medical devices themselves.
- the coatings or medical devices optionally include a bioactive agent.
- the polymer or polymer blends described herein can be used to form a coating(s) on an implantable device.
- the polymers or polymer blends described herein can also be used to form the implantable device itself.
- the implantable device can optionally include a bioactive agent.
- bioactive agents are paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-l-oxyl (4-amino- TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2- hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2- (2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, ABT-578, clobetasol, prodrugs thereof, co-drugs thereof, and combinations thereof.
- the implantable device can be implanted in a patient to treat or prevent a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
- a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
- Figure 1 shows the number of platelets adhered to the surface of a poly(methacrylate) polymer coating.
- Figure 2 shows the total amount of proteins from human plasma adsorbed onto the surface of a poly(methacrylate) polymer coating.
- coating or implantable medical device formed of a polymer having non-fouling pendant groups.
- the polymer defined herein can be used alone or in combination with another biocompatible polymer and/or a biobeneficial material to form coatings on implantable medical devices or to form the implantable medical devices themselves.
- the coatings or medical devices optionally include a bioactive agent.
- bioactive agents are paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-l-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2- hydroxy)ethyl-raparnycin (everolimus), 40-O-(3-hydroxy) ⁇ ropyl-rapamycin, 40-O-[2- (2-hydroxy)ethoxy]ethyl-rapamycin, 40- ⁇ 9-tetrazole-rapamycin, ABT-578, clobetasol, prodrugs thereof, co-drugs thereof, and combinations thereof.
- the implantable device can be implanted in a patient to treat, prevent or ameliorate a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, plaque rupture in type 2 diabetes, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
- a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, plaque rupture in type 2 diabetes, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
- polymers formed of monomers having non-fouling pendant groups can be a polymer that contains repeating units of Formula I:
- R 1 , R 2 , R 3 , R 4 and R 5 are independently H, C1-C4 alkyl such as CH 3 , ethyl, propyl, isopropyl, isobutyl, sec-butyl, or n-butyl, silyl groups, siloxy groups, or phenyl, Z is O or NH,
- X is absence, O, S, or NR 6 where R 6 is H, C1-C4 alkyl such as CH 3 , ethyl, propyl, isopropyl, isobutyl, sec-butyl, or n-butyl, or phenyl, and n can be 0 or a positive integer ranging from, e.g., 1 to 100,000.
- the polymer that contains the repeating units of Formula I can be a homopolymer or a copolymer.
- the copolymer can be statistical, random, alternating, period block or graft copolymer including the repeating units of Formula I and/or other repeating units such as a biocompatible polymer, and/or a biobeneficial material,
- X is O.
- Some representative polymers of Formula I are: poly(2-methoxyethyl acrylate) (PMEA), poly(2-hydroxyethyl acrylate) (PHEA), ⁇ oly(ethyl acrylate) (PEA), ( ⁇ oly(2- ethylhexyl acrylate) (PEHA), poly(2-phenoxyethyl acrylate) (PPEA), ⁇ oly(2- ethoxyethyl acrylate) (PEEA), poly(2-hydroxyethyl methacrylate) (PHEMA), poly(2- methoxyethyl methacrylate) (PMEMA), poly(ethyl methacrylate) (PEMA), (poly(2- ethylhexyl methacrylate) (PEHMA), poly(2-phenoxyethyl methacrylate) (PPEMA), poly(hydroxypropyl methacrylamide), poly(2-ethoxyethyl methacrylate) (PEEM), and combinations thereof.
- R 1 , R 2 , R 3 , R 4 , R 5 , Z and X of Formula I are selected to exclude from Formula I any of the methacrylate or acrylate polymers described in the sections entitled “Polymer blends" or “Biobeneficial material”, below.
- the polymers described herein can be synthesized by methods known in the art (see, for example, D. Braun, et al., Polymer Synthesis: Theory and Practice. Fundamentals, Methods, Experiments. 3 rd Ed., Springer, 2001; Hans R. Kricheldorf, Handbook of Polymer Synthesis, Marcel Dekker Inc., 1992; G. Odian, Principles of Polymerization, 3 rd ed. John Wiley & Sons, 1991).
- one method that can be used to make the polymer can be free radical methods (see, for example, D. Braun, et al., Polymer Synthesis: Theory and Practice. Fundamentals, Methods, Experiments. 3 rd Ed., Springer, 2001; Hans R.
- the polymers described herein can be blended with one or more additional biocompatible polymers having different hydrophilicity and/or flexibility to generate a polymer blend coating material that has desired biocompatibility, flexibility and drug permeability.
- the polymers of the present invention can be bonded, conjugated, grafted or crosslinked with one or more additional biocompatible polymers.
- the polymers can be coated in separate layers.
- the additional biocompatible polymer can be biodegradable (both bioerodable or bioabsorbable) or nondegradable, and can be hydrophilic or hydrophobic. In some embodiments,
- hydrophilic is defined to have a Hildebrand solubility parameter ⁇
- the ⁇ is determined by
- biocompatible polymers include, but are not limited to, poly(ester amide), polyhydroxyalkanoates (PHA), poly(3-hydroxyalkanoates) such as poly(3-hydroxypropanoate), poly(3-hydroxybutyrate), poly(3-hydroxyvalerate), poly(3-hydroxyhexanoate), pory(3-hydroxyheptanoate) andpoly(3- hydroxyoctanoate), poly(4-hydroxyalkanoate) such as poly(4-hydroxybutyrate), poly(4-hydroxyvalerate), poly(4-hydroxyhexanoate), poly(4-hydroxyheptanoate), poly(4-hydroxyoctanoate) and copolymers including any of the 3-hydroxyalkanoate or 4-hydroxyalkanoate monomers or blends thereof, poly polyesters, poly(D,L- lactide), poly(L-lactide), polyglycolide, poly(D,L-lactide-co-glycolide), poly(L- lactide-co
- polyethylene oxide/poly(lactic acid) PEO/PLA
- polyalkylene oxides such as polyethylene oxide), poly(propylene oxide), poly(ether ester), polyalkylene oxalates, polyphosphazenes, phosphoryl choline, choline, poly(aspirin), polymers and copolymers of hydroxyl bearing monomers other than the polymers of Formula I (defined above), PEG acrylate (PEGA), PEG methacrylate, 2- methacryloyloxyethylphosphorylcholine (MPC) and 72-vinyl pyrrolidone (VP), carboxylic acid bearing monomers such as methacrylic acid (MA), acrylic acid (AA), alkoxymethacrylate, alkoxyacrylate, and 3-trimethylsilylpropyl methacrylate (TMSPMA), poly(styrene-isoprene-styrene)-PEG (SIS-PEG), polystyrene-PEG, polyisobuty
- poly(D,L-lactide), poly(L-lactide), poly(D,L-lactide- co-glycolide), and poly(L-lactide-co-glycolide) can be used interchangeably with the terms poly(D,L-lactic acid), poly(L-lactic acid), poly(D,L-lactic acid-co-glycolic acid), and poly(L-lactic acid-co-glycolic acid), respectively.
- the polymers or polymer blends described herein may form a coating on an implantable device such as a stent or form the implantable device such as the stent optionally with a biobeneficial material.
- the combination can be mixed, blended, bonded, conjugated, crosslinked, grafted, or coated in separate layers. In some embodiments, it can be an interpenetrating polymer network (IPN).
- IPN interpenetrating polymer network
- the biobeneficial material useful in the coatings described herein can be a polymeric material or non- polymeric material.
- the biobeneficial material is preferably non-toxic, non-antigenic and non-immunogenic.
- a biobeneficial material is one which enhances the biocompatibility of a device by being non-fouling, hemocompatible, actively non- thrombogenic, or anti-inflammatory, all without depending on the release of a pharmaceutically active agent.
- biobeneficial materials include, but are not limited to, polyethers such as poly(ethylene glycol), copoly(ether-esters) (e.g. PEO/PLA); polyalkylene oxides such as poly(ethylene oxide), poly(propylene oxide), poly(ether ester), polyalkylene oxalates, polyphosphazenes, phosphoryl choline, choline, poly(aspirin), polymers and co-polymers of hydroxyl bearing monomers such as hydroxyethyl methacrylate (HEMA), hydroxypropyl methacrylate (HPMA), hydroxypropylmethacrylamide, poly (ethylene glycol) acrylate (PEGA), PEG methacrylate, 2-methacryloyloxyethylphosphorylcholine (MPC) and H-vinyl pyrrolidone (VP), carboxylic acid bearing monomers such as methacrylic acid (MA), acrylic acid (AA), alkoxymethacrylate, alkoxyacrylate, and 3-trimethyl
- PolyActiveTM refers to a block copolymer having flexible polyethylene glycol) and poly(butylene terephthalate) blocks (PEGT/PBT).
- PolyActiveTM is intended to include AB, ABA, BAB copolymers having such segments of PEG and PBT (e.g., poly(ethylene glycol)-block- poly(butyleneterephthalate)-block polyethylene glycol) (PEG-PBT-PEG).
- the biobeneficial material can be a polyether such as poly (ethylene glycol) (PEG) or polyalkylene oxide.
- the polymer of Formula I or a polymer blend or conjugation (e.g., bonded or grafed) having the polymer of Formula I may form a coating or an implantable device optionally with one or more bioactive agents.
- bioactive agents can be any agent which can be a therapeutic, prophylactic, ameliorative or diagnostic agent.
- agents can have anti-proliferative or anti-inflammmatory properties or can have other properties such as antineoplastic, antiplatelet, anti-coagulant, anti-fibrin, antithrombonic, antimitotic, antibiotic, antiallergic, antioxidant as well as cystostatic agents.
- Suitable therapeutic, prophylactic or ameliorative agents include synthetic inorganic and organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, and DNA and RNA nucleic acid sequences having therapeutic, prophylactic or diagnostic activities.
- Nucleic acid sequences include genes, antisense molecules which bind to complementary DNA to inhibit transcription, and ribozymes.
- bioactive agents include antibodies, receptor ligands, enzymes, adhesion peptides, blood clotting factors, inhibitors or clot dissolving agents such as streptokinase and tissue plasminogen activator, antigens for immunization, hormones and growth factors, oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy.
- anti-proliferative agents include rapamycin and its functional or structural derivatives, 40-0-(2-hydroxy)ethyl-raparnycin (everolimus), and its functional or structural derivatives, and paclitaxel and its functional and structural derivatives.
- rapamycin derivatives examples include 40-epi-(Nl-tetrazolyl)- rapamycin (ABT-578), 40-O-(3-hydroxy) ⁇ ropyl-rapamycin, 40-O-[2-(2- hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.
- paclitaxel derivatives include docetaxel.
- antineoplastics and/or antimitotics include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g.
- Adriamycin ® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin e.g. Mutamycin ® from Bristol-Myers Squibb Co., Stamford, Conn.
- antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D- phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Ilb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, thrombin inhibitors such as Angiomax a (Bio gen, Inc., Cambridge, Mass.), calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists,
- anti-inflammatory agents including steroidal and non-steroidal anti- inflammatory agents include tacrolimus, dexamethasone, clobetasol, combinations thereof.
- cytostatic substance include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten ® and Capozide ® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. Prinivil ® and Prinzide ® from Merck & Co., Inc., Wliitehouse Station, NJ).
- An example of an antiallergic agent is permirolast potassium.
- therapeutic substances or agents which may be appropriate include midostaurin, pimecrolimus, imatinib mesylate, alpha-interferon, bioactive RGD, and genetically engineered epithelial cells.
- the foregoing substances can also be used in the form of prodrugs or co-drugs thereof.
- the foregoing substances are listed by way of example and are not meant to be limiting.
- Other active agents which are currently available or that may be developed in the future are equally applicable.
- the dosage or concentration of the bioactive agent required to produce a favorable therapeutic effect should be less than the level at which the bioactive agent produces toxic effects and greater than the level at which non-therapeutic results are obtained.
- the dosage or concentration of the bioactive agent can depend upon factors such as the particular circumstances of the patient; the nature of the trauma; the nature of the therapy desired; the time over which the ingredient administered resides at the vascular site; and if other active agents are employed, the nature and type of the substance or combination of substances.
- Therapeutic effective dosages can be determined empirically, for example by infusing vessels from suitable animal model systems and using immunohistochemical, fluorescent or electron microscopy methods to detect the agent and its effects, or by conducting suitable in vitro studies. Standard pharmacological test procedures to determine dosages are understood by one of ordinary skill in the art.
- an implantable device may be any suitable medical substrate that can be implanted in a human or veterinary patient.
- implantable devices include self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation, Santa Clara, CA).
- the underlying structure of the device can be of virtually any design.
- the device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), high nitrogen stainless steel, e.g., BIODUR 108, cobalt chrome alloy L-605, "MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof.
- ELGILOY cobalt chromium alloy
- 316L stainless steel
- high nitrogen stainless steel e.g., BIODUR 108, cobalt chrome alloy L-605, "MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof.
- BIODUR 108 cobalt chrome alloy L-605, "MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-tit
- MP35N consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum.
- MP20N consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum.
- Devices made from bioabsorbable or biostable polymers could also be used with the embodiments of the present invention.
- the device itself, such as a stent, can also be made from the described inventive polymers or polymer blends.
- a coating of the various described embodiments can be formed on an implantable device or prosthesis, e.g., a stent.
- the agent will retain on the medical device such as a stent during delivery and expansion of the device, and released at a desired rate and for a predetermined duration of time at the site of implantation.
- bioabsorbable or non-degradable devices can be formed of a material containing the polymer of Formula I.
- the material can be the polymer of Formula I or a polymer blend containing the polymer of Formula I with one or more biocompatible polymers, optionally with a biobeneficial material and/or a bioactive agents, which are defined above.
- the medical device is a stent.
- a stent having the above-described coating is useful for a variety of medical procedures, including, by way of example, treatment of obstructions caused by tumors in bile ducts, esophagus, trachea/bronchi and other biological passageways.
- a stent having the above-described coating is particularly useful for treating occluded regions of blood vessels caused by abnormal or inappropriate migration and proliferation of smooth muscle cells, thrombosis, and restenosis. Stents may be placed in a wide array of blood vessels, both arteries and veins. Representative examples of sites include the iliac, renal, and coronary arteries.
- an angiogram is first performed to determine the appropriate positioning for stent therapy.
- An angiogram is typically accomplished by injecting a radiopaque contrasting agent through a catheter inserted into an artery or vein as an x-ray is taken.
- a guidewire is then advanced through the lesion or proposed site of treatment.
- Over the guidewire is passed a delivery catheter, which allows a stent in its collapsed configuration to be inserted into the passageway.
- the delivery catheter is inserted either percutaneously or by surgery into the femoral artery, brachial artery, femoral vein, or brachial vein, and advanced into the appropriate blood vessel by steering the catheter through the vascular system under fluoroscopic guidance.
- a stent having the above-described coating may then be expanded at the desired area of treatment.
- a post-insertion angiogram may also be utilized to confirm appropriate positioning.
- P comes from hypothesis testing to determine if, in fact, the levels of protein absorption between the various polymers are equivalent (null hypothesis).
- P is the probability, on a scale of zero to one, of wrongly rejecting the null hypothesis if it is in fact true. Consequently, P ⁇ 0.05 means there is less than a 5% chance that the difference seen between the two groups was caused by sampling error. This is often restated to mean there is a 95% confidence that the two groups are different.
- the PMEA coating has both the lowest number of platelets absorbed and the lowest plasma protein absorption of the polymers tested.
- Example 2 Fabrication of a polymer-coated implantable medical device
- Poly(n-butyl methacrylate) is dissolved in 1:1 acetone :xylene (by weight) to give a 2% by weight solution.
- An EFD 780S spray nozzle with a VALVEMATE 7040 control system, manufactured by EFD, Inc., East Buffalo, Rhode Island is used to spray the polymer solution onto a stent.
- the stent can be optionally rotated about its longitudinal axis, at a speed of 50 to about 150 rpm.
- the stent can also be linearly moved along the same axis during the application.
- the 2% solution of the polymer is applied to a 12-mm VISIONTM stent (available from Guidant Corporation) in a series of 10-second passes, to deposit 10 ⁇ g of coating per spray pass. Between the spray passes, the stent is dried for 10 seconds using a flow of air at 80 0 C. Five spray passes are applied to form a 50 ⁇ g primer layer, followed by baking the primer layer at 80 0 C for one hour.
- VISIONTM stent available from Guidant Corporation
- a mixture is prepared that consists of, by weight, 2% of poly(n-butyl methacrylate), 1.0% of everolimus, and 97% of the 1:1 (by weight) acetone: cyclohexanone.
- the same apparatus used to spray the primer layer on the stent is used to apply the drug layer. 10 spray passes are performed to form a 175 ⁇ g drug-polymer layer, followed by drying the drug-polymer layer at 50 0 C for 1 hour.
- a topcoat layer comprising, by weight, 2% poly(2-methoxyethyl acrylate) and 98% 60:40 acetone: cyclohexanone is then applied over the drug-containing layer using the same apparatus used to coat the primer layer and the drug-containing layer. Six spray passes are performed to form a 100 ⁇ g topcoat layer, followed by drying at 50 0 C for 1 hour.
Abstract
Implantable devices formed of or coated with a material that includes a polymer having a non-fouling acrylate or methacrylate polymer are provided. The implantable device can be used for treating or preventing a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
Description
IMPLANTABLE DEVICES FORMED OF NON-FOULING METHACRYLATE
OR ACRYLATE POLYMERS
BACKGROUND OF THE INVENTION Field of the Invention
This invention generally relates to coatings or implantable devices, such as stents or coatings on a stent, formed of a material that contains methacrylates or acrylates having non-fouling pendant groups. Description of the Background
Although stents work well mechanically, the chronic issues of restenosis and, to a lesser extent, stent thrombosis remain. Pharmacological therapy in the form of a drug-delivery stent appears a feasible means to tackle these biologically derived issues. Polymeric coatings placed onto the stent serve to act both as the drug reservoir, and to control the release of the drug. One of the commercially available polymer coated products is stents manufactured by Boston Scientific. For example, U.S. Patent Nos. 5,869,127; 6,099,563; 6,179,817; and 6,197,051, assigned to Boston Scientific Corporation, describe various compositions for coating medical devices. These compositions provide to stents described therein an enhanced biocompatibility and may optionally include a bioactive agent. U.S. Patent No. 6,231,590 to Scimed Life Systems, Inc., describes a coating composition, which includes a bioactive agent, a collagenous material, or a collagenous coating optionally containing or coated with other bioactive agents.
A current paradigm in biomaterials is the control of protein adsorption on the implant surface. Uncontrolled protein adsorption, leading to mixed layer of partially
denatured proteins, is a hallmark of current biomaterials when implanted. Such a surface presents different cell binding sites from adsorbed plasma proteins such as fibrogen and immunogloblulin G. Platelets and inflammatory cells such as monocyte/macrophages and neutrophils adhere to these surfaces. Unfavorable events can be controlled by the use of non-fouling surfaces. These are materials, which absorb little or no protein, primarily due to their hydrophilic surface properties.
Another limitation of current drug-delivery stents stems from the fact that the stent is a foreign body. Use of drug-delivery stents has proved successful by use of controlled release of antiproliferative or anti-inflammatory drugs to control restenosis. However, drug-delivery stents still have a small, but measurable, incidence of sub-acute thrombosis. Moreover, drug-delivery stents have not driven restenosis to zero levels, especially in more challenging patient subsets such as diabetics or patients with small vessels, and/or long, diffuse lesions. A biomaterials- based strategy for further improving the outcome of drug-delivery stents is by the use of biobeneficial materials or surfaces in stent coatings. A biobeneficial material is one which enhances the biocompatibility of a device by being non-fouling, hemocompatible, actively non-thrombogenic, or anti-inflammatory, all without depending on the release of a pharmaceutically active agent.
Some of the currently used polymeric materials such as poly(vinylidene fluoride-co-hexafluoropropene) have good mechanical properties, and acceptable biocompatibility, but also have low permeability to drugs. One proposed solution to ameliorate this issue is to blend in hydrophilic polymers. However, it is well known in the art that many hydrophilic materials such as polyethylene oxide or hyaluronic acid are water-soluble and can be leached out of the composition such that the coating
may lose biobeneficiality. Such polymeric blends can also have compromised mechanical properties, particularly the ultimate elongation.
The present invention addresses such problems by providing a polymeric material for coating implantable devices by providing polymeric materials from which the device can be made. SUMMARY OF THE INVENTION
Provided herein is a coating or implantable medical device formed of a polymer having non-fouling pendant groups. hi one embodiment, the polymer can be a polymer that contains repeating units of Formula I:
where:
R1, R2, R3, R4 and R5 are independently H, C1-C4 alkyl such as CH3, ethyl, propyl, isopropyl, isobutyl, sec-butyl, or n-butyl, silyl groups, siloxy groups, and phenyl,
Z is O or NH,
X is absence, O, S, or NR6 where R6 is H, C1-C4 alkyl such as CH3, ethyl, propyl, isopropyl, or n-butyl, and phenyl, and n can be 0 or a positive integer ranging from, e.g., 1 to 100,000.
The polymer that contains the repeating units of Formula I can be a homopolymer or a copolymer. The copolymer can be, statistical, random, alternating, periodic block or graft copolymer including the repeating units of Formula I, and include other repeating units such as a biocompatible polymer, and/or a biobeneficial material.
The polymer defined herein can be used alone or in combination with another biocompatible polymer and/or a biobeneficial material to form coatings on implantable medical devices or to form the implantable medical devices themselves. In some embodiments, the coatings or medical devices optionally include a bioactive agent.
The polymer or polymer blends described herein can be used to form a coating(s) on an implantable device. The polymers or polymer blends described herein can also be used to form the implantable device itself. The implantable device can optionally include a bioactive agent. Some exemplary bioactive agents are paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-l-oxyl (4-amino- TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2- hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2- (2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, ABT-578, clobetasol, prodrugs thereof, co-drugs thereof, and combinations thereof. The implantable device can be implanted in a patient to treat or prevent a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication,
anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the number of platelets adhered to the surface of a poly(methacrylate) polymer coating.
Figure 2 shows the total amount of proteins from human plasma adsorbed onto the surface of a poly(methacrylate) polymer coating.
DETAILED DESCRIPTION
Provided herein is coating or implantable medical device formed of a polymer having non-fouling pendant groups. The polymer defined herein can be used alone or in combination with another biocompatible polymer and/or a biobeneficial material to form coatings on implantable medical devices or to form the implantable medical devices themselves. In some embodiments, the coatings or medical devices optionally include a bioactive agent. Some exemplary bioactive agents are paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-l-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2- hydroxy)ethyl-raparnycin (everolimus), 40-O-(3-hydroxy)ρropyl-rapamycin, 40-O-[2- (2-hydroxy)ethoxy]ethyl-rapamycin, 40-<9-tetrazole-rapamycin, ABT-578, clobetasol, prodrugs thereof, co-drugs thereof, and combinations thereof. The implantable device can be implanted in a patient to treat, prevent or ameliorate a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, plaque rupture in type 2 diabetes, chronic total
occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
Polymers formed of monomers having non-fouling pendant groups In one embodiment, the polymer can be a polymer that contains repeating units of Formula I:
R1, R2, R3, R4 and R5 are independently H, C1-C4 alkyl such as CH3, ethyl, propyl, isopropyl, isobutyl, sec-butyl, or n-butyl, silyl groups, siloxy groups, or phenyl, Z is O or NH,
X is absence, O, S, or NR6 where R6 is H, C1-C4 alkyl such as CH3, ethyl, propyl, isopropyl, isobutyl, sec-butyl, or n-butyl, or phenyl, and n can be 0 or a positive integer ranging from, e.g., 1 to 100,000.
The polymer that contains the repeating units of Formula I can be a homopolymer or a copolymer. The copolymer can be statistical, random, alternating, period block or graft copolymer including the repeating units of Formula I and/or other repeating units such as a biocompatible polymer, and/or a biobeneficial material,
both defined below.
In some embodiments, in the polymer of Formula I, X is O.
Some representative polymers of Formula I are: poly(2-methoxyethyl acrylate) (PMEA), poly(2-hydroxyethyl acrylate) (PHEA), ρoly(ethyl acrylate) (PEA), (ρoly(2- ethylhexyl acrylate) (PEHA), poly(2-phenoxyethyl acrylate) (PPEA), ρoly(2- ethoxyethyl acrylate) (PEEA), poly(2-hydroxyethyl methacrylate) (PHEMA), poly(2- methoxyethyl methacrylate) (PMEMA), poly(ethyl methacrylate) (PEMA), (poly(2- ethylhexyl methacrylate) (PEHMA), poly(2-phenoxyethyl methacrylate) (PPEMA), poly(hydroxypropyl methacrylamide), poly(2-ethoxyethyl methacrylate) (PEEM), and combinations thereof.
In some embodiments, R1, R2, R3, R4, R5, Z and X of Formula I are selected to exclude from Formula I any of the methacrylate or acrylate polymers described in the sections entitled "Polymer blends" or "Biobeneficial material", below.
The polymers described herein can be synthesized by methods known in the art (see, for example, D. Braun, et al., Polymer Synthesis: Theory and Practice. Fundamentals, Methods, Experiments. 3rd Ed., Springer, 2001; Hans R. Kricheldorf, Handbook of Polymer Synthesis, Marcel Dekker Inc., 1992; G. Odian, Principles of Polymerization, 3rd ed. John Wiley & Sons, 1991). For example, one method that can be used to make the polymer can be free radical methods (see, for example, D. Braun, et al., Polymer Synthesis: Theory and Practice. Fundamentals, Methods, Experiments. 3rd Ed., Springer, 2001; Hans R. Kricheldorf, Handbook of Polymer Synthesis, Marcel Dekker Inc., 1992). Polymerization by suspension or emulsion techniques utilizing free radical initiation is commonly employed. Block copolymers and terpolymers can be produced by atom transfer polymerization. Polymerization in solvent can also be used to synthesize the polymers described herein.
Polymer blends or conjugation
In another embodiment, the polymers described herein can be blended with one or more additional biocompatible polymers having different hydrophilicity and/or flexibility to generate a polymer blend coating material that has desired biocompatibility, flexibility and drug permeability. In other embodiments, the polymers of the present invention can be bonded, conjugated, grafted or crosslinked with one or more additional biocompatible polymers. In some embodiments, the polymers can be coated in separate layers.
The additional biocompatible polymer can be biodegradable (both bioerodable or bioabsorbable) or nondegradable, and can be hydrophilic or hydrophobic. In some
embodiments, hydrophilic is defined to have a Hildebrand solubility parameter δ
value greater than about 8.5 (cal/cm ) , e.g., greater than about 9.5 (cal/cm ) ,
greater than about 10.5 (cal/cm3)1 2 or about 11.5 (cal/cm3)1 2. The δ is determined by
the following equation:
δ = (ΔE/V)1/2
where ΔE is the energy of vaporization, cal/mole, and V is the molar volume,
cm3/mole.
Representative biocompatible polymers include, but are not limited to, poly(ester amide), polyhydroxyalkanoates (PHA), poly(3-hydroxyalkanoates) such as poly(3-hydroxypropanoate), poly(3-hydroxybutyrate), poly(3-hydroxyvalerate), poly(3-hydroxyhexanoate), pory(3-hydroxyheptanoate) andpoly(3- hydroxyoctanoate), poly(4-hydroxyalkanoate) such as poly(4-hydroxybutyrate), poly(4-hydroxyvalerate), poly(4-hydroxyhexanoate), poly(4-hydroxyheptanoate), poly(4-hydroxyoctanoate) and copolymers including any of the 3-hydroxyalkanoate
or 4-hydroxyalkanoate monomers or blends thereof, poly polyesters, poly(D,L- lactide), poly(L-lactide), polyglycolide, poly(D,L-lactide-co-glycolide), poly(L- lactide-co-glycolide), polycaprolactone, poly(lactide-co-caprolactone), poly(glycolide-co-caprolactone), poly(dioxanone), poly(ortho esters), poly(anhydrides), poly(tyrosine carbonates) and derivatives thereof, poly(tyrosine ester) and derivatives thereof, poly(imino carbonates), poly(glycolic acid-co- trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), polycyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), polyurethanes, polyphosphazenes, silicones, polyesters, polyolefms, polyisobutylene and ethylene-alphaolefm copolymers, acrylic polymers and copolymers, vinyl lialide polymers and copolymers, such as polyvinyl chloride, polyvinyl ethers, such as polyvinyl methyl ether, polyvinylidene halides, such as polyvinylidene chloride, polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics, such as polystyrene, polyvinyl esters, such as polyvinyl acetate, copolymers of vinyl monomers with each other and olefins, such as ethylene-methyl methacrylate copolymers, acrylonitrile- styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers, polyamides, such as Nylon 66 and polycaprolactam, alkyd resins, polycarbonates, polyoxymethylenes, polyimides, polyethers, poly(glyceryl sebacate), poly(propylene fumarate), epoxy resins, polyurethanes, rayon, rayon-triacetate, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, carboxymethyl cellulose, polyethers such as poly(ethylene glycol) (PEG), copoly(ether-esters) (e.g. polyethylene oxide/poly(lactic acid) (PEO/PLA)), polyalkylene oxides such as polyethylene oxide), poly(propylene oxide), poly(ether ester), polyalkylene oxalates,
polyphosphazenes, phosphoryl choline, choline, poly(aspirin), polymers and copolymers of hydroxyl bearing monomers other than the polymers of Formula I (defined above), PEG acrylate (PEGA), PEG methacrylate, 2- methacryloyloxyethylphosphorylcholine (MPC) and 72-vinyl pyrrolidone (VP), carboxylic acid bearing monomers such as methacrylic acid (MA), acrylic acid (AA), alkoxymethacrylate, alkoxyacrylate, and 3-trimethylsilylpropyl methacrylate (TMSPMA), poly(styrene-isoprene-styrene)-PEG (SIS-PEG), polystyrene-PEG, polyisobutylene-PEG, polycaprolactone-PEG (PCL-PEG), PLA-PEG, poly(methyl methacrylate)-PEG (PMMA-PEG), polydimethylsiloxane-co-PEG (PDMS-PEG), poly(vinylidene fluoride)-PEG (PVDF-PEG), PLURONIC™ surfactants (polypropylene oxide-co-polyethylene glycol), poly(tetramethylene glycol), hydroxy functional poly( vinyl pyrrolidone), biomolecules such as collagen, alginate, fibrin, fibrinogen, albumin, cellulose, starch, collagen, dextran, dextrin, fragments and derivatives of hyaluronic acid, heparin, fragments and derivatives of heparin, glycosamino glycan (GAG), GAG derivatives, polysaccharide, elastin, chitosan, alginate, and combinations thereof. In some embodiments, the polymer can exclude any one of the aforementioned polymers.
As used herein, the terms poly(D,L-lactide), poly(L-lactide), poly(D,L-lactide- co-glycolide), and poly(L-lactide-co-glycolide) can be used interchangeably with the terms poly(D,L-lactic acid), poly(L-lactic acid), poly(D,L-lactic acid-co-glycolic acid), and poly(L-lactic acid-co-glycolic acid), respectively.
Biobeneficial Material
The polymers or polymer blends described herein may form a coating on an implantable device such as a stent or form the implantable device such as the stent
optionally with a biobeneficial material. The combination can be mixed, blended, bonded, conjugated, crosslinked, grafted, or coated in separate layers. In some embodiments, it can be an interpenetrating polymer network (IPN). The biobeneficial material useful in the coatings described herein can be a polymeric material or non- polymeric material. The biobeneficial material is preferably non-toxic, non-antigenic and non-immunogenic. A biobeneficial material is one which enhances the biocompatibility of a device by being non-fouling, hemocompatible, actively non- thrombogenic, or anti-inflammatory, all without depending on the release of a pharmaceutically active agent.
Representative biobeneficial materials include, but are not limited to, polyethers such as poly(ethylene glycol), copoly(ether-esters) (e.g. PEO/PLA); polyalkylene oxides such as poly(ethylene oxide), poly(propylene oxide), poly(ether ester), polyalkylene oxalates, polyphosphazenes, phosphoryl choline, choline, poly(aspirin), polymers and co-polymers of hydroxyl bearing monomers such as hydroxyethyl methacrylate (HEMA), hydroxypropyl methacrylate (HPMA), hydroxypropylmethacrylamide, poly (ethylene glycol) acrylate (PEGA), PEG methacrylate, 2-methacryloyloxyethylphosphorylcholine (MPC) and H-vinyl pyrrolidone (VP), carboxylic acid bearing monomers such as methacrylic acid (MA), acrylic acid (AA), alkoxymethacrylate, alkoxyacrylate, and 3-trimethylsilylpropyl methacrylate (TMSPMA), poly(styrene-isoprene-styrene)-PEG (SIS-PEG), polystyrene-PEG, polyisobutylene-PEG, polycaprolactone-PEG (PCL-PEG), PLA- PEG, ρoly(methyl methacrylate) -PEG (PMMA-PEG), polydimethylsiloxane-co-PEG (PDMS-PEG), poly(vinylidene fluoride)-PEG (PVDF-PEG), PLURONIC™ surfactants (polypropylene oxide-co-polyethylene glycol), poly(tetramethylene
glycol), hydroxy functional polyvinyl pyrrolidone), biomolecules such as fibrin, fibrinogen, albumin, cellulose, starch, collagen, dextran, dextrin, hyaluronic acid, fragments and derivatives of hyaluronic acid, heparin, fragments and derivatives of heparin, glycosamino glycan (GAG), GAG derivatives, polysaccharide, elastin, chitosan, alginate, silicones, PolyActive™, and combinations thereof. In some embodiments, the coating can exclude any one of the aforementioned polymers.
The term PolyActive™ refers to a block copolymer having flexible polyethylene glycol) and poly(butylene terephthalate) blocks (PEGT/PBT). PolyActive™ is intended to include AB, ABA, BAB copolymers having such segments of PEG and PBT (e.g., poly(ethylene glycol)-block- poly(butyleneterephthalate)-block polyethylene glycol) (PEG-PBT-PEG).
In a preferred embodiment, the biobeneficial material can be a polyether such as poly (ethylene glycol) (PEG) or polyalkylene oxide.
Bioactive Agents
The polymer of Formula I or a polymer blend or conjugation (e.g., bonded or grafed) having the polymer of Formula I may form a coating or an implantable device optionally with one or more bioactive agents. These bioactive agents can be any agent which can be a therapeutic, prophylactic, ameliorative or diagnostic agent. These agents can have anti-proliferative or anti-inflammmatory properties or can have other properties such as antineoplastic, antiplatelet, anti-coagulant, anti-fibrin, antithrombonic, antimitotic, antibiotic, antiallergic, antioxidant as well as cystostatic agents. Examples of suitable therapeutic, prophylactic or ameliorative agents include synthetic inorganic and organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, and DNA and RNA nucleic acid sequences having
therapeutic, prophylactic or diagnostic activities. Nucleic acid sequences include genes, antisense molecules which bind to complementary DNA to inhibit transcription, and ribozymes. Some other examples of other bioactive agents include antibodies, receptor ligands, enzymes, adhesion peptides, blood clotting factors, inhibitors or clot dissolving agents such as streptokinase and tissue plasminogen activator, antigens for immunization, hormones and growth factors, oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy. Examples of anti-proliferative agents include rapamycin and its functional or structural derivatives, 40-0-(2-hydroxy)ethyl-raparnycin (everolimus), and its functional or structural derivatives, and paclitaxel and its functional and structural derivatives. Examples of rapamycin derivatives include 40-epi-(Nl-tetrazolyl)- rapamycin (ABT-578), 40-O-(3-hydroxy)ρropyl-rapamycin, 40-O-[2-(2- hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin. Examples of paclitaxel derivatives include docetaxel. Examples of antineoplastics and/or antimitotics include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. Adriamycin® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D- phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Ilb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, thrombin inhibitors such as Angiomax a (Bio gen, Inc., Cambridge, Mass.), calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF)
antagonists, fish oil (omega 3 -fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station, NJ), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), nitric oxide or nitric oxide donors, super oxide dismutases, super oxide dismutase mimetic, 4- amino-2,2,6,6-tetramethylpiperidine-l-oxyl (4-amino-TEMPO), estradiol, anticancer agents, dietary supplements such as various vitamins, and a combination thereof. Examples of anti-inflammatory agents including steroidal and non-steroidal anti- inflammatory agents include tacrolimus, dexamethasone, clobetasol, combinations thereof. Examples of such cytostatic substance include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. Prinivil® and Prinzide® from Merck & Co., Inc., Wliitehouse Station, NJ). An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents which may be appropriate include midostaurin, pimecrolimus, imatinib mesylate, alpha-interferon, bioactive RGD, and genetically engineered epithelial cells. The foregoing substances can also be used in the form of prodrugs or co-drugs thereof. The foregoing substances are listed by way of example and are not meant to be limiting. Other active agents which are currently available or that may be developed in the future are equally applicable.
The dosage or concentration of the bioactive agent required to produce a favorable therapeutic effect should be less than the level at which the bioactive agent
produces toxic effects and greater than the level at which non-therapeutic results are obtained. The dosage or concentration of the bioactive agent can depend upon factors such as the particular circumstances of the patient; the nature of the trauma; the nature of the therapy desired; the time over which the ingredient administered resides at the vascular site; and if other active agents are employed, the nature and type of the substance or combination of substances. Therapeutic effective dosages can be determined empirically, for example by infusing vessels from suitable animal model systems and using immunohistochemical, fluorescent or electron microscopy methods to detect the agent and its effects, or by conducting suitable in vitro studies. Standard pharmacological test procedures to determine dosages are understood by one of ordinary skill in the art.
Examples of Implantable Device
As used herein, an implantable device may be any suitable medical substrate that can be implanted in a human or veterinary patient. Examples of such implantable devices include self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation, Santa Clara, CA). The underlying structure of the device can be of virtually any design. The device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), high nitrogen stainless steel, e.g., BIODUR 108, cobalt chrome alloy L-605, "MP35N," "MP20N," ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof. "MP35N" and "MP20N" are trade names for alloys of cobalt, nickel, chromium and molybdenum
available from Standard Press Steel Co., Jenkintown, PA. "MP35N" consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. "MP20N" consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. Devices made from bioabsorbable or biostable polymers could also be used with the embodiments of the present invention. The device itself, such as a stent, can also be made from the described inventive polymers or polymer blends.
Method of Use
In accordance with embodiments of the invention, a coating of the various described embodiments can be formed on an implantable device or prosthesis, e.g., a stent. For coatings including one or more active agents, the agent will retain on the medical device such as a stent during delivery and expansion of the device, and released at a desired rate and for a predetermined duration of time at the site of implantation. In accordance with some other embodiments of the invention, bioabsorbable or non-degradable devices can be formed of a material containing the polymer of Formula I. The material can be the polymer of Formula I or a polymer blend containing the polymer of Formula I with one or more biocompatible polymers, optionally with a biobeneficial material and/or a bioactive agents, which are defined above. Preferably, the medical device is a stent. A stent having the above-described coating is useful for a variety of medical procedures, including, by way of example, treatment of obstructions caused by tumors in bile ducts, esophagus, trachea/bronchi and other biological passageways. A stent having the above-described coating is particularly useful for treating occluded regions of blood vessels caused by abnormal or inappropriate migration and proliferation of smooth muscle cells, thrombosis, and restenosis. Stents may be placed in a wide array of blood vessels, both arteries and
veins. Representative examples of sites include the iliac, renal, and coronary arteries.
For implantation of a stent, an angiogram is first performed to determine the appropriate positioning for stent therapy. An angiogram is typically accomplished by injecting a radiopaque contrasting agent through a catheter inserted into an artery or vein as an x-ray is taken. A guidewire is then advanced through the lesion or proposed site of treatment. Over the guidewire is passed a delivery catheter, which allows a stent in its collapsed configuration to be inserted into the passageway. The delivery catheter is inserted either percutaneously or by surgery into the femoral artery, brachial artery, femoral vein, or brachial vein, and advanced into the appropriate blood vessel by steering the catheter through the vascular system under fluoroscopic guidance. A stent having the above-described coating may then be expanded at the desired area of treatment. A post-insertion angiogram may also be utilized to confirm appropriate positioning.
EXAMPLES
The embodiments of the present invention will be illustrated by the following set forth examples. AU parameters and data are not to be construed to unduly limit the scope of the embodiments of the invention.
Example 1. Hemocompatibility study of poly(2-methoxyethyl acrylate) (PMEA)
The measures of in vitro hemocompatibility, including human platelet adhesion, changes in platelet morphology, total absorbed protein from human plasma, amount of absorbed BSA (bovine serum albumin), absorbed human fibrinogen, and changes in protein conformation by circular dichroism of polymers PPEA, PEHA, PEA, PMEA, PHEMA and PHEA were measured (see M, Tanaka M, et al., Biomaterials 21:1471-1481
(2000)). Figure 1 shows number of platelets adhered to the surface of the polymers (**P < 0.01 vs. PMEA, mean ± SD, n = 5), and Figure 2 shows the total amount of proteins from human plasma adsorbed onto polymers (*P < 0.05 vs. PMEA; **P < 0.01 vs. PMEA, mean ± SD, n = 5). hi this statistical analysis, the P value comes from hypothesis testing to determine if, in fact, the levels of protein absorption between the various polymers are equivalent (null hypothesis). Here, P is the probability, on a scale of zero to one, of wrongly rejecting the null hypothesis if it is in fact true. Consequently, P < 0.05 means there is less than a 5% chance that the difference seen between the two groups was caused by sampling error. This is often restated to mean there is a 95% confidence that the two groups are different.
As can be seen, the PMEA coating has both the lowest number of platelets absorbed and the lowest plasma protein absorption of the polymers tested.
Example 2: Fabrication of a polymer-coated implantable medical device
Primer layer
Poly(n-butyl methacrylate) is dissolved in 1:1 acetone :xylene (by weight) to give a 2% by weight solution. An EFD 780S spray nozzle with a VALVEMATE 7040 control system, manufactured by EFD, Inc., East Providence, Rhode Island is used to spray the polymer solution onto a stent. During the process of applying the composition, the stent can be optionally rotated about its longitudinal axis, at a speed of 50 to about 150 rpm. The stent can also be linearly moved along the same axis during the application.
The 2% solution of the polymer is applied to a 12-mm VISION™ stent (available from Guidant Corporation) in a series of 10-second passes, to deposit 10 μg of coating per spray pass. Between the spray passes, the stent is dried for 10 seconds using a
flow of air at 80 0C. Five spray passes are applied to form a 50 μg primer layer, followed by baking the primer layer at 80 0C for one hour.
Drug-containing layer
A mixture is prepared that consists of, by weight, 2% of poly(n-butyl methacrylate), 1.0% of everolimus, and 97% of the 1:1 (by weight) acetone: cyclohexanone. The same apparatus used to spray the primer layer on the stent is used to apply the drug layer. 10 spray passes are performed to form a 175 μg drug-polymer layer, followed by drying the drug-polymer layer at 50 0C for 1 hour.
Biobeneficial topcoat layer
A topcoat layer comprising, by weight, 2% poly(2-methoxyethyl acrylate) and 98% 60:40 acetone: cyclohexanone is then applied over the drug-containing layer using the same apparatus used to coat the primer layer and the drug-containing layer. Six spray passes are performed to form a 100 μg topcoat layer, followed by drying at 50 0C for 1 hour.
While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.
Claims
1. An implantable device having a coating comprising a polymer that comprises repeating units of Formula I:
2. The implantable device of claim 1, wherein R1, R2, R3, R4 and R5, R6 are independently CH3, ethyl, propyl, isopropyl, isobutyl, sec-butyl, or n-butyl, and
wherein Z is O.
3. The implantable device of claim 1, wherein Z is O, and wherein X is O or NH.
4. The implantable device of claim 1 , wherein the polymer is selected from the group consisting of poly(2-methoxyethyl acrylate) (PMEA), poly(2- hydroxyethyl acrylate) (PHEA), poly(ethyl acrylate) (PEA), (ρoly(2-ethylhexyl acrylate) (PEHA), poly(2-phenoxyethyl acrylate) (PPEA), poly(2-ethoxyethyl acrylate) (PEEA), poly(2-hydroxyethyl methacrylate) (PHEMA), poly(2-methoxyethyl methacrylate) (PMEMA), poly(ethyl methacrylate) (PEMA), (poly(2-ethylhexyl methacrylate) (PEHMA), poly(2-phenoxyethyl methacrylate) (PPEMA), poly(2- ethoxyethyl methacrylate) (PEEM), and combinations thereof.
5. The implantable device of claim 1, further comprising a biocompatible polymer, blended or bonded with the polymer according to claim 1.
6. The implantable device of claim 1, further comprising a bioactive agent.
7. The implantable device of claim 9, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6- tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-(9-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, ABT-578, clobetasol, prodrugs thereof, co-drugs thereof, and a combination thereof.
8. The implantable device of claim 1 which is a stent.
9. The implantable device of claim 7, which is a stent.
10. An absorbable device formed of a material comprising a polymer that comprises repeating units of Formula I: wherein R1, R2, R3, R4 and R5 are independently H, C1-C4 alkyl groups, silyl groups, siloxy groups, and phenyl, wherein Z is O or NH, and wherein X is absence, O, S, or NR6 where R6 is H, C1-C4 alkyl, or phenyl.
11. The absorbable device of claim 10, wherein R1, R2, R3, R4 and R5, R6 are independently CH3, ethyl, propyl, isopropyl, or n-butyl, and wherein Z is O.
12. The absorbable device of claim 10, wherein Z is O, and wherein X is O or NH.
13. The absorbable device of claim 10, wherein the polymer is selected from the group consisting of poly(2-methoxyethyl acrylate) (PMEA), poly(2- hydroxyethyl acrylate) (PHEA), poly(ethyl acrylate) (PEA), (poly(2-ethylhexyl acrylate) (PEHA), poly(2-phenoxyethyl acrylate) (PPEA), poly(2-ethoxyethyl acrylate) (PEEA), ρoly(2-hydroxyethyl methacrylate) (PHEMA), poly(2-methoxyethyl methacrylate) (PMEMA), poly(ethyl methacrylate) (PEMA), (poly(2-ethylhexyl methacrylate) (PEHMA), poly(2-phenoxyethyl methacrylate) (PPEMA), poly(2- ethoxyethyl methacrylate) (PEEM), and combinations thereof.
14. The absorbable device of claim 10, further comprising a bioactive agent.
15. The implantable device of claim 14, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6- tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, ABT-578, clobetasol, prodrugs thereof, co-drugs thereof, and a combination thereof.
16. The implantable device of claim 10 which is a stent.
17. A method of treating a disorder in a patient comprising implanting in the patient the impantable device of claim 9, wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.
18. A method of treating a disorder in a patient comprising implanting in the patient the impantable device of claim 16, wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06748556.5A EP1866003B1 (en) | 2005-03-24 | 2006-03-20 | Implantable devices formed of non-fouling methacrylate or acrylate polymers |
JP2008503133A JP2008534062A (en) | 2005-03-24 | 2006-03-20 | Implantable devices formed from nonfouling methacrylate or acrylate polymers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/089,774 US7700659B2 (en) | 2005-03-24 | 2005-03-24 | Implantable devices formed of non-fouling methacrylate or acrylate polymers |
US11/089,774 | 2005-03-24 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006102418A2 true WO2006102418A2 (en) | 2006-09-28 |
WO2006102418A9 WO2006102418A9 (en) | 2006-11-23 |
WO2006102418A3 WO2006102418A3 (en) | 2007-04-19 |
Family
ID=36917293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/010420 WO2006102418A2 (en) | 2005-03-24 | 2006-03-20 | Implantable devices formed of non-fouling methacrylate or acrylate polymers |
Country Status (4)
Country | Link |
---|---|
US (3) | US7700659B2 (en) |
EP (1) | EP1866003B1 (en) |
JP (1) | JP2008534062A (en) |
WO (1) | WO2006102418A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011006507A2 (en) | 2009-07-15 | 2011-01-20 | Technical University Of Denmark | Polymer coating comprising 2-methoxyethyl acrylate units synthesized by surface-initiated atom transfer radical polymerization |
EP2987464A4 (en) * | 2013-04-18 | 2016-12-21 | Nat Univ Corp Yamagata Univ | Stent to be placed in bile duct and process for producing same |
JP2017136166A (en) * | 2016-02-02 | 2017-08-10 | テルモ株式会社 | Medical supply and production method of the same |
US11464952B2 (en) | 2018-05-03 | 2022-10-11 | Microvention, Inc. | Treatment for hydrocephalus |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
US7563483B2 (en) * | 2003-02-26 | 2009-07-21 | Advanced Cardiovascular Systems Inc. | Methods for fabricating a coating for implantable medical devices |
US9381279B2 (en) * | 2005-03-24 | 2016-07-05 | Abbott Cardiovascular Systems Inc. | Implantable devices formed on non-fouling methacrylate or acrylate polymers |
US7700659B2 (en) | 2005-03-24 | 2010-04-20 | Advanced Cardiovascular Systems, Inc. | Implantable devices formed of non-fouling methacrylate or acrylate polymers |
US7713541B1 (en) | 2006-11-21 | 2010-05-11 | Abbott Cardiovascular Systems Inc. | Zwitterionic terpolymers, method of making and use on medical devices |
EP2097119A4 (en) * | 2006-11-21 | 2012-10-17 | Abbott Lab | Use of a terpolymer of tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride in drug eluting coatings |
WO2008094706A2 (en) | 2007-02-01 | 2008-08-07 | Cook Incorporated | Closure device and method of closing a bodily opening |
US8617205B2 (en) | 2007-02-01 | 2013-12-31 | Cook Medical Technologies Llc | Closure device |
US20080286332A1 (en) | 2007-05-14 | 2008-11-20 | Pacetti Stephen D | Implantable medical devices with a topcoat layer of phosphoryl choline acrylate polymer for reduced thrombosis, and improved mechanical properties |
US8734483B2 (en) * | 2007-08-27 | 2014-05-27 | Cook Medical Technologies Llc | Spider PFO closure device |
US8025495B2 (en) * | 2007-08-27 | 2011-09-27 | Cook Medical Technologies Llc | Apparatus and method for making a spider occlusion device |
US20090062838A1 (en) * | 2007-08-27 | 2009-03-05 | Cook Incorporated | Spider device with occlusive barrier |
US8308752B2 (en) * | 2007-08-27 | 2012-11-13 | Cook Medical Technologies Llc | Barrel occlusion device |
US8092822B2 (en) | 2008-09-29 | 2012-01-10 | Abbott Cardiovascular Systems Inc. | Coatings including dexamethasone derivatives and analogs and olimus drugs |
EP2627265B8 (en) | 2010-10-15 | 2019-02-20 | Cook Medical Technologies LLC | Occlusion device for blocking fluid flow through bodily passages |
US10940167B2 (en) | 2012-02-10 | 2021-03-09 | Cvdevices, Llc | Methods and uses of biological tissues for various stent and other medical applications |
AU2014214700B2 (en) | 2013-02-11 | 2018-01-18 | Cook Medical Technologies Llc | Expandable support frame and medical device |
WO2018209306A1 (en) * | 2017-05-12 | 2018-11-15 | Microvention, Inc. | Medical devices |
JP7358030B2 (en) * | 2018-01-31 | 2023-10-10 | 住友ゴム工業株式会社 | Hydrophilic base material |
Family Cites Families (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4117235A (en) * | 1971-09-23 | 1978-09-26 | Owens-Illinois, Inc. | Novel preparation of novel low molecular weight, liquid polymer |
US4156034A (en) * | 1974-03-20 | 1979-05-22 | Hitachi, Ltd. | Liquid developer for electro photography |
JPS50136315A (en) * | 1974-04-17 | 1975-10-29 | ||
US4273760A (en) * | 1979-02-05 | 1981-06-16 | National Starch And Chemical Corporation | Shampoo compositions |
US4612209A (en) * | 1983-12-27 | 1986-09-16 | Ciba-Geigy Corporation | Process for the preparation of heat-curable adhesive films |
CA1281479C (en) * | 1986-04-22 | 1991-03-12 | Noriyuki Tsuboniwa | Blocked isocyanatocarbonyl group-containing polymers, and their production and use |
US6387379B1 (en) * | 1987-04-10 | 2002-05-14 | University Of Florida | Biofunctional surface modified ocular implants, surgical instruments, medical devices, prostheses, contact lenses and the like |
JP2641452B2 (en) * | 1987-07-27 | 1997-08-13 | 株式会社日立製作所 | Pattern formation method |
US5019096A (en) * | 1988-02-11 | 1991-05-28 | Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
US4931287A (en) * | 1988-06-14 | 1990-06-05 | University Of Utah | Heterogeneous interpenetrating polymer networks for the controlled release of drugs |
US6746770B1 (en) * | 1989-05-26 | 2004-06-08 | Internatonal Business Machines Corporation | Electrically conductive and abrasion/scratch resistant polymeric materials, method of fabrication thereof and uses thereof |
US5721299A (en) * | 1989-05-26 | 1998-02-24 | International Business Machines Corporation | Electrically conductive and abrasion/scratch resistant polymeric materials, method of fabrication thereof and uses thereof |
JPH03229745A (en) * | 1990-02-05 | 1991-10-11 | Junkosha Co Ltd | Insulation material |
US5258020A (en) * | 1990-09-14 | 1993-11-02 | Michael Froix | Method of using expandable polymeric stent with memory |
US5163952A (en) * | 1990-09-14 | 1992-11-17 | Michael Froix | Expandable polymeric stent with memory and delivery apparatus and method |
US6248129B1 (en) * | 1990-09-14 | 2001-06-19 | Quanam Medical Corporation | Expandable polymeric stent with memory and delivery apparatus and method |
JP2806510B2 (en) * | 1990-10-18 | 1998-09-30 | テルモ 株式会社 | Artificial organ membrane or medical device |
US5385795A (en) * | 1991-03-08 | 1995-01-31 | Nippon Oil Co., Ltd. | Method for producing color filter |
US5314770A (en) * | 1991-04-26 | 1994-05-24 | Nippon Oil Co., Ltd. | Method for producing color filter |
US5214541A (en) * | 1991-06-12 | 1993-05-25 | Nippon Oil Co., Ltd. | Method for producing color filter |
US5334468A (en) * | 1991-07-09 | 1994-08-02 | Nippon Oil Co., Ltd. | Method for producing color filter |
US5500760A (en) * | 1991-09-06 | 1996-03-19 | Donnelly Corporation | Electrochemichromic solutions, processes for preparing and using the same, and devices manufactured with the same |
US5357636A (en) * | 1992-06-30 | 1994-10-25 | Dresdner Jr Karl P | Flexible protective medical gloves and methods for their use |
JP2949391B2 (en) * | 1992-08-04 | 1999-09-13 | 日石三菱株式会社 | Manufacturing method of color filter |
DE69426040T2 (en) | 1993-02-26 | 2001-05-17 | Donnelly Corp | Electrochromic polymeric solid films, manufacture of electrochromic devices with such films, and processes for the manufacture of such solid films and devices |
US5910854A (en) * | 1993-02-26 | 1999-06-08 | Donnelly Corporation | Electrochromic polymeric solid films, manufacturing electrochromic devices using such solid films, and processes for making such solid films and devices |
US5730966A (en) * | 1993-07-01 | 1998-03-24 | The Procter & Gamble Company | Thermoplastic elastomeric copolymers used in hair and skin care compositions |
SG72661A1 (en) * | 1993-07-01 | 2000-05-23 | Procter & Gamble | Thermoplastic elastomeric copolymers and hair and skin care compositions containing the same |
BR9407017A (en) * | 1993-07-01 | 1996-09-10 | Procter & Gamble | Thermoplastic elastomeric copolymers and skin and hair care compositions containing the same |
WO1995006079A1 (en) * | 1993-08-23 | 1995-03-02 | The Procter & Gamble Company | Silicone grafted thermoplastic elastomeric copolymers and hair and skin care compositions containing the same |
WO1995006078A1 (en) * | 1993-08-23 | 1995-03-02 | The Procter & Gamble Company | Silicone grafted thermoplastic elastomeric copolymers and hair and skin care compositions containing the same |
US5661219A (en) * | 1993-09-06 | 1997-08-26 | Nof Corporation | Curable composition, thermal latent acid catalyst, method of coating, coated article, method of molding and molded article |
DE4444577B4 (en) * | 1993-12-15 | 2005-02-10 | Bridgestone Corp. | Method for producing an optical waveguide |
US5453530A (en) | 1994-03-11 | 1995-09-26 | The Curators Of The University Of Missouri | S-(ω-hydroxyalkyl) esters of thioacrylic and thiomethacrylic acids |
WO1995024929A2 (en) | 1994-03-15 | 1995-09-21 | Brown University Research Foundation | Polymeric gene delivery system |
MA23592A1 (en) | 1994-06-30 | 1995-12-31 | Procter & Gamble | COMPOSITIONS FOR BODY CARE CONTAINING THERMOPLASTIC ELASTOMERIC GRAFT COPOLYMERS |
WO1996011671A1 (en) * | 1994-10-12 | 1996-04-25 | Focal, Inc. | Targeted delivery via biodegradable polymers |
US6291620B1 (en) * | 1994-11-09 | 2001-09-18 | E. I. Du Pont De Nemours And Company | Polymer synthesis |
WO1996019513A1 (en) * | 1994-12-22 | 1996-06-27 | Mitsubishi Rayon Co., Ltd. | Block copolymer and process for producing the same |
DE19547738B4 (en) * | 1994-12-22 | 2007-10-18 | Bridgestone Corp. | Optical waveguide tube and method for its manufacture |
US6179817B1 (en) * | 1995-02-22 | 2001-01-30 | Boston Scientific Corporation | Hybrid coating for medical devices |
US5869127A (en) * | 1995-02-22 | 1999-02-09 | Boston Scientific Corporation | Method of providing a substrate with a bio-active/biocompatible coating |
US5674242A (en) * | 1995-06-06 | 1997-10-07 | Quanam Medical Corporation | Endoprosthetic device with therapeutic compound |
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
CA2178541C (en) * | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US7611533B2 (en) | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
US7550005B2 (en) | 1995-06-07 | 2009-06-23 | Cook Incorporated | Coated implantable medical device |
TW504387B (en) * | 1995-09-06 | 2002-10-01 | Kao Corp | Emulsified, water-in-oil type composition and skin cosmetic preparation |
US5723219A (en) * | 1995-12-19 | 1998-03-03 | Talison Research | Plasma deposited film networks |
US5753146A (en) * | 1996-03-29 | 1998-05-19 | Transitions Optical, Inc. | Photochromic naphthopyran compositions of neutral color |
US5770115A (en) * | 1996-04-19 | 1998-06-23 | Ppg Industries, Inc. | Photochromic naphthopyran compositions of improved fatigue resistance |
US5932299A (en) * | 1996-04-23 | 1999-08-03 | Katoot; Mohammad W. | Method for modifying the surface of an object |
AU3765697A (en) * | 1996-08-08 | 1998-03-06 | Danionics A/S | High voltage electrochromic devices, the method of preparation thereof and the use of a specific non-aqueous electrolyte in electrochromic devices |
US6174329B1 (en) * | 1996-08-22 | 2001-01-16 | Advanced Cardiovascular Systems, Inc. | Protective coating for a stent with intermediate radiopaque coating |
US6197844B1 (en) * | 1996-09-13 | 2001-03-06 | 3M Innovative Properties Company | Floor finish compositions |
US6530951B1 (en) * | 1996-10-24 | 2003-03-11 | Cook Incorporated | Silver implantable medical device |
EP0841353A1 (en) * | 1996-11-07 | 1998-05-13 | Witco GmbH | Process for the preparation of polymeric binders and their application as antifouling paint |
JP3695024B2 (en) * | 1996-11-14 | 2005-09-14 | Jsr株式会社 | Radiation sensitive resin composition for semiconductor device manufacturing |
US5859127A (en) * | 1996-11-29 | 1999-01-12 | Shin-Etsu Polymer Co., Ltd. | Thermosetting resin composition and two-parts composite body thereof with silcone rubber |
US5997517A (en) * | 1997-01-27 | 1999-12-07 | Sts Biopolymers, Inc. | Bonding layers for medical device surface coatings |
US6498163B1 (en) | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
DE69833747T2 (en) * | 1997-04-18 | 2006-11-16 | Kaneka Corp. | POLYMERS, METHOD FOR THE PRODUCTION THEREOF, AND HARDENABLE COMPOSITIONS MADE THEREFOR |
US6113883A (en) * | 1997-04-25 | 2000-09-05 | The Procter & Gamble Company | Hair styling compositions comprising silicone-containing copolymers |
US6555117B2 (en) * | 1997-04-25 | 2003-04-29 | The Procter & Gamble Company | Personal care compositions containing linear toughened silicone grafted polymers |
US6136296A (en) * | 1997-04-25 | 2000-10-24 | The Procter & Gamble Company | Personal care compositions |
US5919879A (en) * | 1997-04-25 | 1999-07-06 | The Procter & Gamble Company | Linear toughened silicone grafted polymers |
US5929173A (en) * | 1997-05-12 | 1999-07-27 | The Procter & Gamble Company | Toughened grafted polymers |
US6165457A (en) | 1997-05-12 | 2000-12-26 | The Procter & Gamble Company | Personal care compositions containing toughened grafted polymers |
US5986015A (en) * | 1997-05-16 | 1999-11-16 | The Procter & Gamble Company | Method of making graft polymers |
US6180632B1 (en) * | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6159978A (en) | 1997-05-28 | 2000-12-12 | Aventis Pharmaceuticals Product, Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6245760B1 (en) * | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
CA2294917C (en) * | 1997-06-18 | 2009-01-06 | Boston Scientific Corporation | Polycarbonate-polyurethane dispersions for thrombo-resistant coatings |
US6110483A (en) * | 1997-06-23 | 2000-08-29 | Sts Biopolymers, Inc. | Adherent, flexible hydrogel and medicated coatings |
US6646354B2 (en) * | 1997-08-22 | 2003-11-11 | Micron Technology, Inc. | Adhesive composition and methods for use in packaging applications |
JPH1189929A (en) * | 1997-09-17 | 1999-04-06 | Terumo Corp | Indwelling catheter |
US6039872A (en) * | 1997-10-27 | 2000-03-21 | Pall Corporation | Hydrophilic membrane |
US6083393A (en) * | 1997-10-27 | 2000-07-04 | Pall Corporation | Hydrophilic membrane |
JP3930984B2 (en) * | 1997-12-12 | 2007-06-13 | 日東電工株式会社 | Transdermal preparation |
US6133391A (en) * | 1998-03-17 | 2000-10-17 | 3M Innovative Properties Company | Adhesive compositions and adhesive tapes comprising zwitterionic copolymers, and novel zwitterionic copolymers |
US6258371B1 (en) * | 1998-04-03 | 2001-07-10 | Medtronic Inc | Method for making biocompatible medical article |
US20030040790A1 (en) | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
WO1999055396A1 (en) * | 1998-04-27 | 1999-11-04 | Surmodics, Inc. | Bioactive agent release coating |
US20020188037A1 (en) | 1999-04-15 | 2002-12-12 | Chudzik Stephen J. | Method and system for providing bioactive agent release coating |
AU4645299A (en) * | 1998-07-08 | 2000-02-01 | Advanced Biocompatible Coatings Inc. | Biocompatible metallic stents with hydroxy methacrylate coating |
AU771367B2 (en) * | 1998-08-20 | 2004-03-18 | Cook Medical Technologies Llc | Coated implantable medical device |
US6187024B1 (en) * | 1998-11-10 | 2001-02-13 | Target Therapeutics, Inc. | Bioactive coating for vaso-occlusive devices |
US6530950B1 (en) * | 1999-01-12 | 2003-03-11 | Quanam Medical Corporation | Intraluminal stent having coaxial polymer member |
US6210856B1 (en) * | 1999-01-27 | 2001-04-03 | International Business Machines Corporation | Resist composition and process of forming a patterned resist layer on a substrate |
US6143354A (en) * | 1999-02-08 | 2000-11-07 | Medtronic Inc. | One-step method for attachment of biomolecules to substrate surfaces |
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
FR2798589B1 (en) * | 1999-09-16 | 2001-11-30 | Oreal | COSMETIC COMPOSITION COMPRISING AT LEAST ONE SILICONE / ACRYLATE COPOLYMER AND AT LEAST ONE THICKENING AGENT |
US6613432B2 (en) | 1999-12-22 | 2003-09-02 | Biosurface Engineering Technologies, Inc. | Plasma-deposited coatings, devices and methods |
US6403760B1 (en) * | 1999-12-28 | 2002-06-11 | Omnova Solutions Inc. | Monohydric polyfluorooxetane polymer and radiation curable coatings containing a monofunctional polyfluorooxetane polymer |
AU2599501A (en) | 1999-12-29 | 2001-07-09 | Advanced Cardiovascular Systems Inc. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
US20020007215A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020005206A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Antiproliferative drug and delivery device |
US20020007214A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020007213A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
JP4754714B2 (en) | 2000-06-01 | 2011-08-24 | テルモ株式会社 | Intraluminal indwelling |
US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
AU8852601A (en) * | 2000-09-06 | 2002-03-22 | Appleton Paper Inc | In situ microencapsulated adhesive |
WO2002024249A2 (en) * | 2000-09-22 | 2002-03-28 | Koole Levinas H | Method for immobilizing poly(hema) on stents |
JP4404468B2 (en) * | 2000-09-29 | 2010-01-27 | テルモ株式会社 | Blood filter and manufacturing method thereof |
US7261735B2 (en) | 2001-05-07 | 2007-08-28 | Cordis Corporation | Local drug delivery devices and methods for maintaining the drug coatings thereon |
US20020111590A1 (en) | 2000-09-29 | 2002-08-15 | Davila Luis A. | Medical devices, drug coatings and methods for maintaining the drug coatings thereon |
US20020051730A1 (en) | 2000-09-29 | 2002-05-02 | Stanko Bodnar | Coated medical devices and sterilization thereof |
EP1322280A1 (en) | 2000-10-03 | 2003-07-02 | Unilever Plc | Cosmetic and personal care compositions |
US7077859B2 (en) | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US20020082679A1 (en) | 2000-12-22 | 2002-06-27 | Avantec Vascular Corporation | Delivery or therapeutic capable agents |
US6663662B2 (en) | 2000-12-28 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Diffusion barrier layer for implantable devices |
US6541537B1 (en) * | 2001-01-19 | 2003-04-01 | Renaissance Technology Llc | Acrylate polymeric compositions and methods |
WO2002064014A2 (en) | 2001-02-09 | 2002-08-22 | Endoluminal Therapeutics, Inc. | Endomural therapy |
WO2002072014A2 (en) | 2001-03-08 | 2002-09-19 | Volcano Therapeutics, Inc. | Medical devices, compositions and methods for treating vulnerable plaque |
CA2444894C (en) | 2001-04-26 | 2013-06-25 | Control Delivery Systems, Inc. | Sustained release drug delivery system containing codrugs |
JP4725941B2 (en) * | 2001-05-23 | 2011-07-13 | 楠本化成株式会社 | Smoothing agent for powder coating |
US7247313B2 (en) * | 2001-06-27 | 2007-07-24 | Advanced Cardiovascular Systems, Inc. | Polyacrylates coatings for implantable medical devices |
JP4162931B2 (en) * | 2001-06-28 | 2008-10-08 | テルモ株式会社 | Cardiopulmonary circuit system |
EP1429689A4 (en) | 2001-09-24 | 2006-03-08 | Medtronic Ave Inc | Rational drug therapy device and methods |
US7195640B2 (en) | 2001-09-25 | 2007-03-27 | Cordis Corporation | Coated medical devices for the treatment of vulnerable plaque |
US20030065377A1 (en) | 2001-09-28 | 2003-04-03 | Davila Luis A. | Coated medical devices |
US6939376B2 (en) * | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US6627584B2 (en) * | 2002-01-28 | 2003-09-30 | Ethyl Corporation | Automatic transmission fluid additive comprising reaction product of hydrocarbyl acrylates and dihydrocarbyldithiophosphoric acids |
US6846892B2 (en) | 2002-03-11 | 2005-01-25 | Johnson & Johnson Vision Care, Inc. | Low polydispersity poly-HEMA compositions |
US7005137B1 (en) | 2002-06-21 | 2006-02-28 | Advanceed Cardiovascular Systems, Inc. | Coating for implantable medical devices |
US7070798B1 (en) * | 2002-06-21 | 2006-07-04 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine |
US7217426B1 (en) | 2002-06-21 | 2007-05-15 | Advanced Cardiovascular Systems, Inc. | Coatings containing polycationic peptides for cardiovascular therapy |
US7396539B1 (en) | 2002-06-21 | 2008-07-08 | Advanced Cardiovascular Systems, Inc. | Stent coatings with engineered drug release rate |
US7083646B2 (en) | 2002-06-28 | 2006-08-01 | Bausch & Lomb Incorporated | Surface modification of functional group-containing intraocular lenses |
US7094256B1 (en) | 2002-12-16 | 2006-08-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical device containing polycationic peptides |
JP2004298223A (en) * | 2003-03-28 | 2004-10-28 | Terumo Corp | Biocompatible material |
US7563454B1 (en) | 2003-05-01 | 2009-07-21 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices |
US20040225345A1 (en) * | 2003-05-05 | 2004-11-11 | Fischell Robert E. | Means and method for stenting bifurcated vessels |
US7700659B2 (en) | 2005-03-24 | 2010-04-20 | Advanced Cardiovascular Systems, Inc. | Implantable devices formed of non-fouling methacrylate or acrylate polymers |
-
2005
- 2005-03-24 US US11/089,774 patent/US7700659B2/en not_active Expired - Fee Related
-
2006
- 2006-03-20 EP EP06748556.5A patent/EP1866003B1/en not_active Not-in-force
- 2006-03-20 WO PCT/US2006/010420 patent/WO2006102418A2/en active Application Filing
- 2006-03-20 JP JP2008503133A patent/JP2008534062A/en active Pending
-
2009
- 2009-11-13 US US12/618,607 patent/US8932615B2/en not_active Expired - Fee Related
-
2014
- 2014-12-09 US US14/565,331 patent/US20150098977A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
D. BRAUN ET AL.: "Polymer Synthesis: Theory and Practice. Fundamentals, Methods, Experiments", 2001, SPRINGER |
G. ODIAN: "Principles of Polymerization", 1991, JOHN WILEY & SONS |
HANS R. KRICHELDORF: "Handbook of Polymer Synthesis", 1992, MARCEL DEKKER INC. |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011006507A2 (en) | 2009-07-15 | 2011-01-20 | Technical University Of Denmark | Polymer coating comprising 2-methoxyethyl acrylate units synthesized by surface-initiated atom transfer radical polymerization |
EP2453942A2 (en) * | 2009-07-15 | 2012-05-23 | Technical University of Denmark | Polymer coating comprising 2-methoxyethyl acrylate units synthesized by surface-initiated atom transfer radical polymerization |
EP2453942A4 (en) * | 2009-07-15 | 2013-01-09 | Univ Denmark Tech Dtu | Polymer coating comprising 2-methoxyethyl acrylate units synthesized by surface-initiated atom transfer radical polymerization |
EP2987464A4 (en) * | 2013-04-18 | 2016-12-21 | Nat Univ Corp Yamagata Univ | Stent to be placed in bile duct and process for producing same |
US10080640B2 (en) | 2013-04-18 | 2018-09-25 | National University Corporation Yamagata University | Stent to be placed in bile duct |
JP2017136166A (en) * | 2016-02-02 | 2017-08-10 | テルモ株式会社 | Medical supply and production method of the same |
US11464952B2 (en) | 2018-05-03 | 2022-10-11 | Microvention, Inc. | Treatment for hydrocephalus |
Also Published As
Publication number | Publication date |
---|---|
US20100119571A1 (en) | 2010-05-13 |
US20060216326A1 (en) | 2006-09-28 |
US7700659B2 (en) | 2010-04-20 |
WO2006102418A3 (en) | 2007-04-19 |
US20150098977A1 (en) | 2015-04-09 |
EP1866003B1 (en) | 2016-08-10 |
EP1866003A2 (en) | 2007-12-19 |
WO2006102418A9 (en) | 2006-11-23 |
US8932615B2 (en) | 2015-01-13 |
JP2008534062A (en) | 2008-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7700659B2 (en) | Implantable devices formed of non-fouling methacrylate or acrylate polymers | |
US9345814B2 (en) | Methacrylate copolymers for medical devices | |
EP1784434B2 (en) | Implantable device from polymers of fluorinated monomers and hydrophilic monomers | |
EP2046848B1 (en) | Random copolymers of methacrylates and acrylates | |
US8105391B2 (en) | Merhods of treatment with devices having a coating containing pegylated hyaluronic acid and a pegylated non-hyaluronic acid polymer | |
WO2006124365A2 (en) | Endothelial cell binding coatings for rapid encapsulation of bioerodable stents | |
WO2006049913A1 (en) | Poly(ester amide) filler blends for modulation of coating properties | |
US20080095918A1 (en) | Coating construct with enhanced interfacial compatibility | |
EP2038319A1 (en) | Block copolymers including a methoxyethyl methacrylate midblock | |
US9381279B2 (en) | Implantable devices formed on non-fouling methacrylate or acrylate polymers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2008503133 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2006748556 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006748556 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |